Mainstream

Hmnc brain health and spruce biosciences announce first patient dosed in phase 2 tamarind trial for major depressive disorder

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder

Topline Results Anticipated in the First Half of 2026

MUNICH,…Read More

You might also be interested in reading Trump-Backed Crypto Firm Loses Another CEO After $1.5 Billion Token Deal.

July 22, 2025
In Mainstream